Get the Stockscreener App
4.08
1.92%
-0.08
Pre-market:
4.14
0.06
+1.47%
Precigen Inc stock is traded at $4.08, with a volume of 1.75M.
It is down -1.92% in the last 24 hours and up +3.82% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$4.16
Open:
$4.13
24h Volume:
1.75M
Relative Volume:
0.40
Market Cap:
$1.44B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-2.9147
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
-1.21%
1M Performance:
+3.82%
6M Performance:
-1.45%
1Y Performance:
+163.23%
1-Day Range:
$4.06
$4.185
1-Week Range:
$3.92
$4.24
52-Week Range:
$1.225
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.08 | 1.44B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now? - Insider Monkey
Precigen, Inc. (PGEN) reports Q4 loss, lags revenue estimates - MSN
Precigen (NASDAQ: PGEN) 2026 proxy details director, pay and equity plan votes - Stock Titan
Precigen (PGEN) price target increased by 11.76% to 9.69 - MSN
Precigen gains after 2025 results on Papzimeos' outlook - MSN
These analysts boost their forecasts on Precigen following Q4 results - MSN
Top Growth Companies With Insider Stakes In April 2026 - simplywall.st
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Precigen files to sell 143.81M shares of common stock for holders - MSN
Precigen (PGEN) Stock: Technical Risk Signals | Q4 2025: EPS Tops ViewsSocial Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai
PGEN (Precigen) beats Q4 2025 EPS expectations, posts 146.7 percent revenue growth as shares rise 3.27 percent.Recovery Stocks - Cổng thông tin điện tử tỉnh Lào Cai
PGEN (Precigen Inc.) reports narrower Q4 2025 loss than estimates, shares rise slightly on positive investor sentiment.Consensus Forecast - UBND thành phố Hải Phòng
Precigen (PGEN) COO Rutul Shah receives new RSU and stock option grants - Stock Titan
Precigen (PGEN) awards RSUs and stock options to Chief Legal Officer - Stock Titan
Precigen (PGEN) CEO receives large RSU and stock option grants - Stock Titan
Precigen (PGEN) awards CCO 115,000 RSUs and 385,000 options - Stock Titan
Precigen (PGEN) CFO receives 120,000 RSUs and options on 399,000 shares - Stock Titan
Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad US payer coverage - MSN
Wall Street bullish on Precigen (PGEN) as the company transitions to commercial stage - MSN
Precigen (NASDAQ:PGEN) Trading Up 7.5%Still a Buy? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 earnings call transcript - MSN
Is Precigen’s (PGEN) New PAPZIMEOS J-Code Reframing Its Respiratory Growth Narrative? - simplywall.st
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - ACCESS Newswire
Precigen (NASDAQ:PGEN) Trading Down 5.6%Here's Why - MarketBeat
Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy? - Insider Monkey
Aug Closing: Whats the fair value of Precigen Inc stockMarket Performance Recap & Expert Curated Trade Ideas - baoquankhu1.vn
Take Profit: Is Precigen Inc a turnaround storyWeekly Gains Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Precigen, Inc. (PGEN) poised for growth on respiratory papillomatosis treatment prospects - MSN
Wall Street Bullish on Precigen (PGEN) As the Company Transitions to Commercial Stage - Insider Monkey
Take Profit: What are Precigen Incs recent SEC filings showingGap Down & Weekly High Conviction Trade Ideas - baoquankhu1.vn
CapEx per share of Precigen Inc – SWB:I5X - TradingView — Track All Markets
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):